Suzuki Shuhei 鈴木修平

Researcher Number	90637175
Other IDs
Affiliation (Current)	2025: 山形大学, 医学部, 客員研究員
Affiliation (based on the past Project Information) *help	2025: 山形大学, 医学部, 客員研究員 2015 – 2023: 山形大学, 医学部, 助教
Review Section/Research Field	Principal Investigator Basic Section 56010:Neurosurgery-related / Tumor therapeutics / Basic Section 56020:Orthopedics-related Except Principal Investigator Basic Section 56010:Neurosurgery-related
Keywords	Principal Investigator サバイビン / 神経伝達物質 / ドラッグリポジショニング / 薬剤抵抗性 / 膠芽腫 / グリオブラストーマ / 抗精神病薬 / がん幹細胞 / 癌幹細胞 / 癌 … More / メラノコルチン / osimertinib / スピロノラクトン / 薬剤耐性 / ルラシドン / ブレクスピプラゾール / EGFR-TKI / アリピプラゾール / オランザピン / 膵がん / 肺がん / サイコオンコロジー / ドラッグリポジショニグ / セロトニン / ドパミン / 薬剤感受性 / xenograft / 活性酸素種 / JNK / 化学療法 … More Except Principal Investigator 細胞老化 / 髄膜腫 / 高悪性度髄膜腫 / 悪性脳腫瘍 Less

MDM4に着目した、ドラッグリポジショニングによる安全な骨軟部肉腫根治戦略の開発Principal Investigator
- Principal Investigator
  
  鈴木修平
- Project Period (FY)
  2025 – 2027
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56020:Orthopedics-related
- Research Institution
  Yamagata University
メラノコルチン等の神経伝達物質に着目した新たな膠芽腫治療戦略Principal Investigator
- Principal Investigator
  
  鈴木修平
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56010:Neurosurgery-related
- Research Institution
  Yamagata University
ゲムシタビンを基軸とした高悪性度髄膜腫に対する新規化学療法の開発
- Principal Investigator
  
  吉岡孝志
- Project Period (FY)
  2022 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56010:Neurosurgery-related
- Research Institution
  Yamagata University
rRe-challenge to develop new treatment strategies for glioblastoma using EGFR-TKIPrincipal Investigator
- Principal Investigator
  
  Suzuki Shuhei
- Project Period (FY)
  2019 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56010:Neurosurgery-related
- Research Institution
  Yamagata University
cancer stem cell treatment strategy focusing on new atypical antipsychoticsPrincipal Investigator
- Principal Investigator
  
  Suzuki Shuhei
- Project Period (FY)
  2017 – 2019
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Yamagata University
Overcoming the drug resistance of cancer stem cells by targeting JNK pathwayPrincipal Investigator
- Principal Investigator
  
  Suzuki Shuhei
- Project Period (FY)
  2015 – 2016
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Yamagata University

All 2023 2022 2021 2020 2019 2018 2017 2016 2015

All Journal Article Presentation Book

[Book] 月刊「細胞」2017
- Author(s)
  鈴木修平, 吉岡孝志, 岡田雅司.
- Total Pages
  156
- Publisher
  北隆館／ニュー・サイエンス社
- Data Source
  KAKENHI-PROJECT-15K18437
[Journal Article] Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.2023
- Author(s)
  Nakagawa-Saito Y, Mitobe Y, Togashi K, Suzuki S, Sugai A, Kitanaka C, Okada M.
- Journal Title
  
  Anticancer Res.
  
  Volume: 3 Issue: 3 Pages: 1131-1138
- DOI
  10.21873/anticanres.16258
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-22K09202, KAKENHI-PROJECT-21K16867, KAKENHI-PROJECT-19K09449, KAKENHI-PROJECT-21H03040
[Journal Article] Domatinostat Targets the FOXM1?Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents2023
- Author(s)
  Nakagawa-Saito Yurika、Mitobe Yuta、Suzuki Shuhei、Togashi Keita、Sugai Asuka、Kitanaka Chifumi、Okada Masashi
- Journal Title
  
  International Journal of Molecular Sciences
  
  Volume: 24 Issue: 13 Pages: 10817-10817
- DOI
  10.3390/ijms241310817
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K09202, KAKENHI-PROJECT-23K06689, KAKENHI-PROJECT-23K08492, KAKENHI-PROJECT-23K09020, KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-21K16867
[Journal Article] The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo2023
- Author(s)
  Mitobe Yuta、Suzuki Shuhei、Nakagawa-Saito Yurika、Togashi Keita、Sugai Asuka、Sonoda Yukihiko、Kitanaka Chifumi、Okada Masashi
- Journal Title
  
  Biomedicines
  
  Volume: 11 Issue: 7 Pages: 1967-1967
- DOI
  10.3390/biomedicines11071967
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K09202, KAKENHI-PROJECT-22K09250, KAKENHI-PROJECT-23K06689, KAKENHI-PROJECT-23K08492, KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-21K16867
[Journal Article] CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells2023
- Author(s)
  Togashi Keita、Suzuki Shuhei、Mitobe Yuta、Nakagawa-Saito Yurika、Sugai Asuka、Takenouchi Senri、Sugimoto Masahiko、Kitanaka Chifumi、Okada Masashi
- Journal Title
  
  Cancers
  
  Volume: 16 Issue: 1 Pages: 118-118
- DOI
  10.3390/cancers16010118
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K09202, KAKENHI-PROJECT-23K06689, KAKENHI-PROJECT-23K08492, KAKENHI-PROJECT-23K09020, KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-21K16867
[Journal Article] Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells2023
- Author(s)
  Mitobe Yuta、Suzuki Shuhei、Nakagawa-Saito Yurika、Togashi Keita、Sugai Asuka、Sonoda Yukihiko、Kitanaka Chifumi、Okada Masashi
- Journal Title
  
  Cancers
  
  Volume: 15 Issue: 17 Pages: 4326-4326
- DOI
  10.3390/cancers15174326
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-22K09202, KAKENHI-PROJECT-22K09250, KAKENHI-PROJECT-23K06689, KAKENHI-PROJECT-23K08492, KAKENHI-PROJECT-23K09020, KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-21K16867, KAKENHI-PROJECT-21H03040
[Journal Article] HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny2022
- Author(s)
  Nakagawa-Saito Yurika、Saitoh Shinichi、Mitobe Yuta、Sugai Asuka、Togashi Keita、Suzuki Shuhei、Kitanaka Chifumi、Okada Masashi
- Journal Title
  
  International Journal of Molecular Sciences
  
  Volume: 23 Issue: 15 Pages: 8084-8084
- DOI
  10.3390/ijms23158084
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-22K09250, KAKENHI-PROJECT-21K16867, KAKENHI-PROJECT-21H03040, KAKENHI-PROJECT-19K09449
[Journal Article] Inhibition of the Phospholipase Cε-c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties2022
- Author(s)
  Okada Masashi、Nakagawa-Saito Yurika、Mitobe Yuta、Sugai Asuka、Togashi Keita、Suzuki Shuhei、Kitanaka Chifumi
- Journal Title
  
  International Journal of Molecular Sciences
  
  Volume: 23 Issue: 15 Pages: 8785-8785
- DOI
  10.3390/ijms23158785
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-22K09202, KAKENHI-PROJECT-22K09250, KAKENHI-PROJECT-21K16867, KAKENHI-PROJECT-21H03040, KAKENHI-PROJECT-19K09449
[Journal Article] CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.2022
- Author(s)
  Mitobe Y, Nakagawa-Saito Y, Togashi K, Suzuki S, Sugai A, Matsuda KI, Sonoda Y, Kitanaka C, Okada M.
- Journal Title
  
  Anticancer Res.
  
  Volume: 10 Issue: 10 Pages: 4727-4733
- DOI
  10.21873/anticanres.15977
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-22K09202, KAKENHI-PROJECT-22K09250, KAKENHI-PROJECT-21K16867, KAKENHI-PROJECT-21H03040, KAKENHI-PROJECT-19K09449
[Journal Article] Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins2022
- Author(s)
  Yamamoto Masahiro、Suzuki Shuhei、Togashi Keita、Sugai Asuka、Okada Masashi、Kitanaka Chifumi
- Journal Title
  
  Cancers
  
  Volume: 14 Issue: 7 Pages: 1706-1706
- DOI
  10.3390/cancers14071706
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K18870, KAKENHI-PROJECT-21K16867, KAKENHI-PROJECT-22K09250, KAKENHI-PROJECT-19K09449
[Journal Article] Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin2021
- Author(s)
  SUZUKI SHUHEI、YAMAMOTO MASAHIRO、SANOMACHI TOMOMI、TOGASHI KEITA、SEINO SHIZUKA、SUGAI ASUKA、YOSHIOKA TAKASHI、OKADA MASASHI、KITANAKA CHIFUMI
- Journal Title
  
  Anticancer Research
  
  Volume: 41 Issue: 9 Pages: 4321-4331
- DOI
  10.21873/anticanres.15237
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K18870, KAKENHI-PROJECT-19K09449, KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-21K16867
[Journal Article] Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1?JNK axis2020
- Author(s)
  Suzuki Shuhei、Okada Masashi、Sanomachi Tomomi、Togashi Keita、Seino Shizuka、Sato Atsushi、Yamamoto Masahiro、Kitanaka Chifumi
- Journal Title
  
  Journal of Biological Chemistry
  
  Volume: 295 Issue: 52 Pages: 18328-18342
- DOI
  10.1074/jbc.ra120.015223
- Peer Reviewed / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-19K09449, KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-19K18870
[Journal Article] Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing2020
- Author(s)
  Suzuki Shuhei、Yamamoto Masahiro、Sanomachi Tomomi、Togashi Keita、Sugai Asuka、Seino Shizuka、Okada Masashi、Yoshioka Takashi、Kitanaka Chifumi
- Journal Title
  
  Biomedicines
  
  Volume: 8 Issue: 8 Pages: 273-273
- DOI
  10.3390/biomedicines8080273
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K09449, KAKENHI-PROJECT-20K07631, KAKENHI-PROJECT-18H02908
[Journal Article] Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs2019
- Author(s)
  Sanomachi Tomomi、Suzuki Shuhei、Togashi Keita、Sugai Asuka、Seino Shizuka、Okada Masashi、Yoshioka Takashi、Kitanaka Chifumi、Yamamoto Masahiro
- Journal Title
  
  Cancers
  
  Volume: 11 Issue: 10 Pages: 1550-1550
- DOI
  10.3390/cancers11101550
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K09449, KAKENHI-PROJECT-16K07160
[Journal Article] In vitro and in vivo Anti-Tumor Effects of Brexpiprazole, a Newly-Developed Serotonin-Dopamine Activity Modulator With an Improved Safety Profile2019
- Author(s)
  Shuhei Suzuki, Masahiro Yamamoto, Keita Togashi, Tomomi Sanomachi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanaka, Masashi Okada
- Journal Title
  
  Oncotarget
  
  Volume: 37 Issue: 37 Pages: 3547-3558
- DOI
  10.18632/oncotarget.26949
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K07160, KAKENHI-PROJECT-17K15015
[Journal Article] Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction2019
- Author(s)
  Suzuki Shuhei、Yamamoto Masahiro、Sanomachi Tomomi、Togashi Keita、Sugai Asuka、Seino Shizuka、Yoshioka Takashi、Kitanaka Chifumi、Okada Masashi
- Journal Title
  
  Cancers
  
  Volume: 11 Issue: 7 Pages: 947-947
- DOI
  10.3390/cancers11070947
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-19K09449, KAKENHI-PROJECT-16K07160, KAKENHI-PROJECT-17K15015
[Journal Article] Brexpiprazole Reduces Survivin and Reverses EGFR Tyrosine Kinase Inhibitor Resistance in Lung and Pancreatic Cancer2019
- Author(s)
  Tomomi Sanomachi, Shuhei Suzuki, Keita Togashi, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanaka , Masashi Okada, Masahiro Yamamoto
- Journal Title
  
  Anticancer Res
  
  Volume: 9 Issue: 9 Pages: 4817-4828
- DOI
  10.21873/anticanres.13667
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K07160, KAKENHI-PROJECT-17K15015
[Journal Article] Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells.2018
- Author(s)
  Suzuki S, Okada M, Takeda H, Kuramoto K, Sanomachi T, Togashi K, Seino S, Yamamoto M, Yoshioka T, Kitanaka C.
- Journal Title
  
  Oncotarget.
  
  Volume: 9 Issue: 66 Pages: 32667-32679
- DOI
  10.18632/oncotarget.25994
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K07160, KAKENHI-PROJECT-17K15015
[Journal Article] Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.2017
- Author(s)
  Sanomachi T, Suzuki S, Kuramoto K, Takeda H, Sakaki H, Togashi K, Seino S, Yoshioka T, Okada M, Kitanaka C.
- Journal Title
  
  Anticancer Res.
  
  Volume: 37 Issue: 11 Pages: 6177-6188
- DOI
  10.21873/anticanres.12067
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-16K07160, KAKENHI-PROJECT-17K15015
[Journal Article] Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance.2016
- Author(s)
  Suzuki S, Okada M, Kuramoto K, Takeda H, Sakaki H, Watarai H, Sanomachi T, Seino S, Yoshioka T, Kitanaka C.
- Journal Title
  
  Anticancer Res.
  
  Volume: 10 Pages: 5153-5161
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K18437
[Journal Article] Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel2016
- Author(s)
  Seino M, Okada M, Sakaki H, Takeda H, Watarai H, Suzuki S, Seino S, Kuramoto K, Ohta T, Nagase S, Kurachi H, Kitanaka C
- Journal Title
  
  Oncology Reports
  
  Volume: 35 Issue: 1 Pages: 593-601
- DOI
  10.3892/or.2015.4377
- Peer Reviewed / Acknowledgement Compliant / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-15K20125, KAKENHI-PROJECT-26830065, KAKENHI-PROJECT-15K18437, KAKENHI-PROJECT-16K18410
[Journal Article] Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine.2016
- Author(s)
  Takeda H, Okada M, Suzuki S, Kuramoto K, Sakaki H, Watarai H, Sanomachi T, Seino S, Yoshioka T, Kitanaka C.
- Journal Title
  
  Anticancer Res.
  
  Volume: 12 Pages: 6311-6318
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K18437
[Journal Article] The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo.2016
- Author(s)
  Okada M, Kuramoto K, Takeda H, Watarai H, Sakaki H, Seino S, Seino M, Suzuki S, Kitanaka C.
- Journal Title
  
  Oncotarget
  
  Volume: 19 Issue: 19 Pages: 27021-27032
- DOI
  10.18632/oncotarget.8395
- Peer Reviewed / Acknowledgement Compliant / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26830065, KAKENHI-PROJECT-15H04946, KAKENHI-PROJECT-15K18437, KAKENHI-PROJECT-15K20125, KAKENHI-PROJECT-16K07160, KAKENHI-PROJECT-16K18410
[Journal Article] Impact of H3K27 Demethylase Inhibitor GSKJ4 on NSCLC Cells Alone and in Combination with Metformin.2016
- Author(s)
  Watarai H, Okada M, Kuramoto K, Takeda H, Sakaki H, Suzuki S, Seino S, Oizumi H, Sadahiro M, Kitanaka C.
- Journal Title
  
  Anticancer Res.
  
  Volume: 11 Pages: 6083-6092
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-15K18437
[Journal Article] GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells.2015
- Author(s)
  Sakaki H, Okada M, Kuramoto K, Takeda H, Watarai H, Suzuki S, Seino S, Seino M, Ohta T, Nagase
- Journal Title
  
  Anticancer Res.
  
  Volume: 35 Pages: 6607-6614
- Peer Reviewed / Acknowledgement Compliant
- Data Source
  KAKENHI-PROJECT-15K18437
[Presentation] Brexpiprazole, a Serotonin Dopamine Modulator, Can Sensitize Glioma Stem Cells to Osimertinib via Survivin Reduction2021
- Author(s)
  鈴木修平、佐野町友美、山本雅大、岡田雅司、吉岡孝志、北中千史
- Organizer
  第80回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-19K09449
[Presentation] 部分的ドパミン受容体アゴニストであるアリピプラゾールは癌幹細胞への抗腫瘍効果を示し、薬剤抵抗性を減弱させる2018
- Author(s)
  鈴木修平, 岡田雅司, 吉岡孝志, 北中千史.
- Organizer
  第77回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-17K15015
[Presentation] 膵癌幹細胞がもつ薬剤耐性へのＪＮＫの関与.2015
- Author(s)
  鈴木修平,吉岡孝志
- Organizer
  第19回日本がん分子標的治療学会学術集会
- Place of Presentation
  松山全日空ホテル（愛媛県松山市）
- Year and Date
  2015-06-11
- Data Source
  KAKENHI-PROJECT-15K18437

1. 吉岡孝志 (90271981)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
2. OKADA Masashi

# of Collaborated Projects: 0 results

# of Collaborated Products: 9 results
3. 清野学

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results
4. 冨樫敬太

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results

Suzuki Shuhei 鈴木 修平

Research Projects

Research Products

Co-Researchers

MDM4に着目した、ドラッグリポジショニングによる安全な骨軟部肉腫根治戦略の開発Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

メラノコルチン等の神経伝達物質に着目した新たな膠芽腫治療戦略Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

ゲムシタビンを基軸とした高悪性度髄膜腫に対する新規化学療法の開発

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

rRe-challenge to develop new treatment strategies for glioblastoma using EGFR-TKIPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

cancer stem cell treatment strategy focusing on new atypical antipsychoticsPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Overcoming the drug resistance of cancer stem cells by targeting JNK pathwayPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Book] 月刊「細胞」2017

Author(s)

Total Pages

Publisher

Data Source

[Journal Article] Givinostat Inhibition of Sp1-dependent MGMT Expression Sensitizes Glioma Stem Cells to Temozolomide.2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Domatinostat Targets the FOXM1?Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells2023

Author(s)

Journal Title

DOI

Data Source

[Journal Article] HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Inhibition of the Phospholipase Cε-c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties2022

Author(s)

Journal Title

DOI

Data Source

Suzuki Shuhei 鈴木修平